Search results
Results from the WOW.Com Content Network
The term sundowning was coined by nurse Lois K. Evans in 1987 due to the association between the person's increased confusion and the setting of the sun. [2] [3] For people with sundown syndrome, a multitude of behavioral problems begin to occur and are associated with long-term adverse outcomes.
Also known as “sundowner’s syndrome,” sundowning is a set of symptoms or behaviors that can be seen in some people with Alzheimer’s disease and dementia, according to the Alzheimer’s ...
In contrast to most other antipsychotic drugs, which tend to be somewhat aversive and often show problems with patient compliance with prescribed medication regimes, quetiapine is sometimes associated with drug misuse and abuse potential, for its hypnotic and sedative effects. It has a limited potential for misuse, usually only in individuals ...
Wandering (especially if combined with sundowning) can result in the person being lost outdoors at night, dressed inappropriately, and unable to take many ordinarily routine steps to ensure his or her personal safety and security. This is a situation of great urgency, and the necessity of searching at night imposes added risks on the searchers.
In a mouse study, researchers found that zolpidem (Ambien), a common sleep aid, could prevent the brain from effectively clearing up 'waste', though it remains unclear whether this could affect ...
Allergy medications may cause brain damage, increase dementia risk because of course they can, everything can. Alex Lasker. Updated July 14, 2016 at 10:50 PM.
The causes of persisting symptoms are a combination of pharmacological factors such as persisting drug induced receptor changes, psychological factors both caused by the drug and separate from the drug and possibly in some cases, particularly high dose users, structural brain damage or structural neuronal damage.
Medications are used to reverse the symptoms of extrapyramidal side effects caused by antipsychotics or other drugs, by either directly or indirectly increasing dopaminergic neurotransmission. The treatment varies by the type of the EPS, but may involve anticholinergic agents such as procyclidine, benztropine, diphenhydramine, and trihexyphenidyl.